SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kau-88400"
 

Sökning: onr:"swepub:oai:DiVA.org:kau-88400" > Regional difference...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005770naa a2200553 4500
001oai:DiVA.org:kau-88400
003SwePub
008220204s2011 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-884002 URI
0247 a https://doi.org/10.1016/j.bone.2011.05.0072 DOI
040 a (SwePub)kau
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Díez-Pérez, Adolfou Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III, Barcelona, Spain4 aut
2451 0a Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)
264 1b Elsevier,c 2011
338 a print2 rdacarrier
520 a PurposeTo determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors.MethodsThe Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥ 55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status.ResultsAmong 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥ 65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45–52% versus 62–65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5–3.1) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4–1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment.ConclusionsThe likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis.
650 7a NATURVETENSKAPx Matematikx Sannolikhetsteori och statistik0 (SwePub)101062 hsv//swe
650 7a NATURAL SCIENCESx Mathematicsx Probability Theory and Statistics0 (SwePub)101062 hsv//eng
7001 a Hooven, Frederick H.u University of Massachusetts Medical School, Worcester, MA, USA4 aut
7001 a Adachi, Jonathan D.u St Joseph's Hospital, McMaster University, Hamilton, ON, Canada4 aut
7001 a Adami, Silvanou University of Verona, Ospedale, Verona, Valeggio, Italy4 aut
7001 a Anderson, Frederick A.u University of Massachusetts Medical School, Worcester, MA, USA4 aut
7001 a Boonen, Stevenu Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium4 aut
7001 a Chapurlat, Rolandu Université de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot, Lyon, France4 aut
7001 a Compston, Juliet E.u University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK4 aut
7001 a Cooper, Cyrusu University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford, Oxford, UK4 aut
7001 a Delmas, Pierreu Hôpital Edouard Herriot, Lyon, France4 aut
7001 a Greenspan, Susan L.u University of Pittsburgh, PA, USA4 aut
7001 a LaCroix, Andrea Z.u Fred Hutchinson Cancer Research Center, Seattle, WA, USA4 aut
7001 a Lindsay, Robertu Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA4 aut
7001 a Netelenbos, J. Coenu Department of Endocrinology, VU University Medical Center, Amsterdam, Netherlands4 aut
7001 a Pfeilschifter, Johannesu Alfried Krupp Krankenhaus, Department of Internal Medicine III, Essen, Germany4 aut
7001 a Roux, Christianu Paris Descartes University, Cochin Hospital, Paris, France4 aut
7001 a Saag, Kenneth G.u University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, USA4 aut
7001 a Sambrook, Philipu University of Sydney-Royal North Shore Hospital, St. Leonards, Sydney, NSW, Australia4 aut
7001 a Silverman, Stuartu Cedars-Sinai Medical Center, Los Angeles, CA, USA4 aut
7001 a Siris, Ethel S.u Columbia University Medical Center, New York, NY, USA4 aut
7001 a Watts, Nelson B.u Bone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA4 aut
7001 a Nika, Grigoru University of Massachusetts Medical School, Worcester, MA, USA4 aut0 (Swepub:kau)grignika
7001 a Gehlbach, Stephen H.u University of Massachusetts Medical School, Worcester, MA, USA4 aut
7102 a Hospital del Mar-IMIM, Autonomous University of Barcelona and RETICEF, Instituto Carlos III, Barcelona, Spainb University of Massachusetts Medical School, Worcester, MA, USA4 org
7730 t Boned : Elsevierg 49:3, s. 493-498q 49:3<493-498x 8756-3282x 1873-2763
8564 u https://europepmc.org/articles/pmc4897770?pdf=render
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-88400
8564 8u https://doi.org/10.1016/j.bone.2011.05.007

Hitta via bibliotek

  • Bone (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy